A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination with nivolumab. This is the first study in which BMS-986249 will be given to humans.
This study is closed
Mark Stein, MD
|Do you have a solid tumor that continues to spread, has come back, or cannot be removed completely by surgery?
|Are you able to walk, care for yourself, and do light physical activities?